 | Up a level |
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2023). Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 42(2), p. 168. Nature Publishing Group 10.1038/s41388-022-02555-9
Kinner, M; Prehn, C; Schneider, R; Schroeder, C; Kolb, E; Gold, R; Hoepner, R; Chan, A (2021). Course of neuropsychological impairment during Natalizumab associated progressive multifocal leukoencephalopathy. European journal of neurology, 28(3), pp. 921-927. Wiley 10.1111/ene.14604
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2011). Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 30(25), pp. 2823-35. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2011.10
